BioSpace News Archive

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Abiomed, maker of the Impella heart pump, is taking a number of steps to aid the global medical community and contribute to improved patient care during the COVID-19 outbreak.

CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD, PhD.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has completed its first shipment of bottled cannabis topicals under a contract manufacturing agreement.

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update in lieu of the changes brought upon by the novel coronavirus (COVID-19) pandemic.

OPKO Health, Inc. (NASDAQ: OPK) today reported interim results from an ongoing Phase 4 clinical trial comparing RAYALDEE® with three common treatment regimens for secondary hyperparathyroidism (SHPT)

Assurance AB™ is a single-use, self-contained SARS-CoV-2 (COVID-19) antibody detection test that provides results in 15-minutes.

Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing.

Baril Corporation and ViruDefense, Inc. today announced that the two companies have been collaborating over the past six weeks to develop high-capacity, US-based manufacturing capabilities of surgical N95-F respirator masks combining the filtration capabilities of N95 masks with the fluid resistance of surgical masks.

Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products. The companies will collaborate on the delivery of Vycellix’s novel RNA immunomodulator VY-M using Avectas’ cell